Literature DB >> 11880955

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Kieren A Marr1, Rachel A Carter, Fulvio Crippa, Anna Wald, Lawrence Corey.   

Abstract

Reports have focused on the emergence of moulds as pathogens in recipients of hematopoietic stem cell transplants. To review the incidence of and risks for mould infections, we examined the records of 5589 patients who underwent hematopoietic stem cell transplantation at the Fred Hutchinson Cancer Research Center (Seattle) from 1985 through 1999. After 1992, the incidence of invasive aspergillosis increased in allograft recipients and remained high through the 1990s. Infections with non-fumigatus Aspergillus species, Fusarium species, and Zygomycetes increased during the late 1990s, especially in patients who received multiple transplants. Although infection caused by Scedosporium species was common in patients who had neutropenia, infection caused by Zygomycetes typically occurred later after transplantation, when patients had graft-versus-host disease. The overall 1-year survival rate was equally poor (similar20%) for all patients with mould infections. The results of the present study demonstrate the changing epidemiology of mould infections, emphasizing the increasing importance of amphotericin B--resistant organisms and the differences in risks and outcome of infection with different filamentous fungi.

Entities:  

Mesh:

Year:  2002        PMID: 11880955     DOI: 10.1086/339202

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  320 in total

1.  Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation.

Authors:  Anil A Panackal; Hong Li; Dimitrios P Kontoyiannis; Motomi Mori; Cheryl A Perego; Michael Boeckh; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

2.  Factors associated with mortality in transplant patients with invasive aspergillosis.

Authors:  John W Baddley; David R Andes; Kieren A Marr; Dimitrios P Kontoyiannis; Barbara D Alexander; Carol A Kauffman; Robert A Oster; Elias J Anaissie; Thomas J Walsh; Mindy G Schuster; John R Wingard; Thomas F Patterson; James I Ito; O Dale Williams; Tom Chiller; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

Review 3.  Sudden death in a patient with bone marrow transplant by a fungus among us.

Authors:  Lemuel Non; Joanna Paula Sta Cruz; Sherilyn Tuazon
Journal:  BMJ Case Rep       Date:  2014-11-12

Review 4.  Fungal diagnostics in pneumonia.

Authors:  Erika D Lease; Barbara D Alexander
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

Review 5.  Specific infectious complications after stem cell transplantation.

Authors:  Holger Hebart; Hermann Einsele
Journal:  Support Care Cancer       Date:  2003-08-15       Impact factor: 3.603

Review 6.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 7.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

9.  Gastrointestinal mucormycosis: an evolving disease.

Authors:  Brad Spellberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

10.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.